Advani, R. H. Et Al. 2022. Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , (Louisiana, United States Of America), 1759-1760.

Advani, R. H., Avigdor, A., Sureda, A., Lavie, D., Hohaus, S., Zaucha, J. M., ... Vu Minh Hua, V. M. H.(2022). Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study . 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) (pp.1759-1760). Louisiana, United States Of America

Advani, Ranjana Et Al. "Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study," 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 2022

Advani, Ranjana H. Et Al. "Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study." 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , Louisiana, United States Of America, pp.1759-1760, 2022

Advani, R. H. Et Al. (2022) . "Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study." 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) , Louisiana, United States Of America, pp.1759-1760.

@conferencepaper{conferencepaper, author={Ranjana H. Advani Et Al. }, title={Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study}, congress name={64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)}, city={Louisiana}, country={United States Of America}, year={2022}, pages={1759-1760} }